Interested in participating?
Register today Or call us on 020 8664 5200 (select option 1) and speak to a member of our Volunteer Recruitment Team.
To qualify for participation in this study you need to:
- Be aged between 18 and 77 years (inclusive) at screening
- Have a documented diagnosis of psoriasis (with a confirmed medical history available from your GP).
- Have a body mass index (BMI) between ≥18.0 and ≤35.0 kg/m2 (inclusive). Your BMI is calculated using the formula: weight (in kilograms) divided by height (in metres) squared).
What is this all about?
Chronic inflammation is most appropriately defined in terms of the process, in which continuing inflammation and attempted tissue healing by repair occur simultaneously. Chronic inflammation results in a variety of diseases, depending on the location of and trigger for the inflammation. These diseases include asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA) and psoriasis but there are many other diseases and disorders caused by chronic inflammation.
Richmond Pharmacology is conducting a clinical trial for a new experimental drug called FX125L. FX125L is an anti-inflammatory agent being developed for the treatment of chronic inflammatory diseases such as asthma, COPD, RA and psoriasis. It is anticipated that FX125L may be more effective and have fewer side effects compared to the current marketed drugs.
This is the first time FX125L will be given to patients with chronic inflammation. The purpose of this study, therefore, is to examine the impact of treatment with such an agent in patients with a range of different diseases that share a chronic inflammatory component. The purpose of this study is also to collect information on markers which will help us to plan future research studies, to further test the effect of this compound.
The trial is being conducted at Richmond Pharmacology Ltd only.
What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 14 to 28 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
Participation for this study requires you to attend 5 out-patient visits and one residential stay of 1 night and 1 day at our clinical unit at Croydon University Hospital. This includes the screening visit (Visit 1) within 14 to 28 days before the start of the study, one residential stay of 1 night/1 day at our unit (Visit 2), 3 outpatient visits on Days 10, 42 and Day 56 (Visits 3, 4 and 5) and the final follow up visit (Visit 6) after the last dose of the study drug. Your participation in this study will last approximately 17 weeks.
Example of a study timetable:
|Trial Schedule||The Days||Number of Visits|
|Screening||Day-28 to Day-14||2|
|Admission & Dosing||Day -1 / Day 1||1|
|Home Dosing||Day 2 to Day 9||0|
|Day Visit to RPL||Day 10||1|
|Home Dosing||Day 11 to Day 41||0|
|Day Visit to RPL||Day 42||1|
|Home Dosing||Day 43 to Day 55||0|
|Day Visit to RPL||Day 56||1|
|Follow up visit||Day 84||1|
What's in it for you?
Apart from doing something good, we will also compensate you for your time in the form of a monetary payment.
You will receive £560 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £280 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for study participation is £840. You will also be compensated for your travel expenses.*
* You will receive travel expenses up to a value of £150 if you are included in the study and following the delivery of valid receipts for travel relating to your participation in this study. All study related travel expenses within the limit of £150 will be paid in conjunction with your study payment following the completion of your participation in the trial.
Want to find out more?
Thank you for your interest in this study. It has now come to completion however if you still wish to register for similar trials
that may take place in the future, please complete our online registration form and we will be in contact when we next have a study that you may be legible for
Call us on 020 8664 5200 (select option 1) to register with a member of our Volunteer Recruitment Team.
Ref: FXT_Oct 2011
C11067_eDM and web story_version 1_24 10 11.docx